Forte Biosciences, Inc.
Forte Biosciences, Inc. (FBRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
fbrx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Forte Biosciences, Inc. (FBRX) measures how much investors pay for each dollar of the company's trailing earnings. FBRX's current PE ratio of N/A is calculated by dividing its stock price of $15.67 by its TTM earnings per share of -$0.43.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Forte Biosciences, Inc.You FBRX | $218M | N/A | — | -$0.43 |
 Actuate Therapeutics Inc ACTU | $44M | N/A | — | -$1.06 |
 Alector, Inc. ALEC | $182M | N/A | — | -$1.39 |
 Applied Therapeutics, Inc. APLT | $15M | N/A | — | -$0.76 |
 Corbus Pharmaceuticals Holdings, Inc. CRBP | $95M | N/A | — | -$5.90 |
 Cardiff Oncology, Inc. CRDF | $103M | N/A | — | -$0.69 |
 Elicio Therapeutics, Inc. ELTX | $259M | N/A | — | -$2.58 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.47 | — | |
2024-12-31 FY2024 | — | $-12.17 | — | |
2023-12-31 FY2023 | — | $-24.92 | — | |
2022-12-31 FY2022 | — | $-19.94 | — | |
2021-12-31 FY2021 | — | $-38.85 | — | |
2020-12-31 FY2020 | — | $-157.93 | — | |
2019-12-31 FY2019 | — | $-48.25 | — | |
2018-12-31 FY2018 | — | $-915.18 | — | |
2017-12-31 FY2017 | — | $-999.38 | — | |
2016-12-31 FY2016 | — | $-634.80 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Forte Biosciences, Inc. (FBRX) measures how much investors pay for each dollar of the company's trailing earnings. FBRX's current PE ratio of N/A is calculated by dividing its stock price of $15.67 by its TTM earnings per share of -$0.43.
Frequently asked questions
FBRX pe ratio · 6 questionsFBRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $15.67 and TTM EPS of -$0.43. Data sourced from Financial Modeling Prep via FBRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Forte Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09